The study aimed to estimate  the role of glucagon-like peptide-1 (GLP-1)  and visfatin as a novel  pro inflammatory marker in Rheumatoid Arthritis (RA ) according to the activity scores of disease to assess the possibility of introducing glucagon-like peptide-1 and visfatin in the diagnosis and monitoring of RA patients and to found the correlation  of visfatin level with GLP-1 and AIP in patients prone to atherosclerosis ,fifty  healthy individuals as control group (G1) and fifty rheumatoid arthritis (RA) patients (G2) were enrolled in this study with middle age  ranged (30 – 40) years and BMI ≥24 kg/m2. ESR ,RF, lipid profile, CRP,insulin, visfatin and GLP-1were determined. Results in t

          Diabetes mellitus (DM) is a metabolic diseases attributed to lack of insulin secretion, insulin activity, or both. The most serious medical problems in hyperglycemia is diabetic nephropathy (DN), originating from the aggregation of inflammatory cells in high numbers. Chitinase 3 like 1 protein (CH3L1P) is a new biomarker for chronic and severe inflammatory conditions. It has been suggested to have a role in the progress of diabetes-associated micro and macro-vascular complications. This paper aims to measure CH3L1P levels and examine their correlation with albuminuria levels in Iraqi patients with type 2 diabetes mellitus (T2DM). Our study involved 66 T2DM patients

Abnormalities in the Lipid and lipoprotein levels are common in the general population and are considered as very important risk- factors for cardiovascular disease .In this context the effect of cholesterol, which is one of the most clinically relevant lipids is very important. Aim of the present study was to determine the levels of GLP-1 and GPCR in non- diabetic dyslipidaemic patients and compare the results with the control group, which may be used as a novel biomarker to predict heart disease in these patients. The study was also aimed to find the relationship between GLP-1 and GPCR with lipid profile and glucagon in the patient group. The study involved 90 non-diabetic dyslipidaemia patients, with 90 healthy controls. The subjects wer

The aim of the present study is to evaluate the change in the levels of glucagon, GLP-1 and GPCR in diabetic patient's and diabetic with dyslipidemia as metabolic syndrome. The study included 75 male aged ranged (30-50) years and with BMI (25-29) kg/m2 which divided into three groups as follows: group one (G1): consist of 25 subjects as healthy control group. Group two (G2): consist of 25 patient's with diabetes mellitus and group three (G3): consist of 25 patient's with diabetic and dyslipidemia as metabolic syndrome. Serum was used in determination of FBG, lipid profile, insulin, glucagon, GLP-1 and GPCR. Whole blood was determination of HbA1c. The results revealed significant elevation in FBG and HbA1c in G2 and G3 comparing to G1. While

The present study conducted on 120 males obese and 50 healthy males, their age
ranged from 20-50 years. The patients were divided into 3 groups based on Body
Mass Index (BMI) and Central Obesity (CO.); it has noticed that there is a
significant relation between both indexes. Effect of the obesity on the lipid profile
was investigated, the results showed that there is an elevated in TG, TC, LDL-C,
VLDL-C and lowered in HDL-C for all three obesity groups compare with control
group. Also, Significant differences (P≤0.05) revealed in TG, TC, LDL-C and
VLDL-C among three obesity groups and the greatest differences recorded in group
III obesity (279.52±1.10, 261.02±1.13, 169.32±1.81, and 55.08±1.33 mg/dl
respec

In order to investigate the levels of reduced glutathione GSH and  α1-antitrypsine in the sera of 20 type 2 diabetic patients and 10 healthy subjects, were enrolled in this study. A significant reduction in GSH level was found in the patient group compared with control.  On the other hand a significant elevation in α1-antitrypsine in patient compared with control was observed.  Correlation between α1-antitrypsine and reduced glutathion was found to be positive (+Ve) for diabetes mellitus type2 patients and negative (-Ve) for healthy control with r values 0.257 and – 0.339 respectively.  In conclusion the depletion of GSH as antioxidant defense insured higher free radical generation in diabetic patients

Both type 1 diabetes and type 2 diabetes have a genetic component, with over 60 chromosomal regions related to type 1 diabetes and over 200 connected with type 2 diabetes at significant genome-wide levels. Numerous single nucleotide polymorphisms in the RETN gene and genetic variables can account for up to 70% of the variations in circulating resistin levels. The RETN polymorphism has been linked in numerous studies to obesity, insulin sensitivity, type 2 diabetes, and cerebrovascular illness. Our objective is to compare this RETN gene 3ʹ-untranslated region polymorphism in type 1 diabetes and type 2 diabetes Iraqi patients. We choose 51 type 1 diabetes and 52 type 2 diabetes patients against 50 healthy subjects (control group) to investig

Background: Diabetic nephropathy (DN) represents the most common cause of end stage renal disease (ESRD) worldwide. Diabetic nephropathy occurs as a result of an interaction between hemodynamic and metabolic factors, however recent evidence shows an increase growing support for the notion that inflammation plays a key role in the pathogenesis of diabetic nephropathy.
Objectives: To speculate the role of IL-18 and TNF-α proinflammatory cytokines in the initiation and development of diabetic nephropathy in T1DM and T2DM.
Materials and methods: Eighty seven T1DM and T2DM patients with or without DN were enrolled. IL-18 and TNF-α cytokines were measured by solid phase immunosorbent assays.
Materials and me

Background: Glycemic control and prevention of secondary complications are the most important aims of using pharmacological treatments in diabetes mellitus. Due to the high incidence of inadequate response to insulin and, we try to evaluate the effects of adjunct use of silymarin with insulin on glycemic control, lipid profile and renal function in type 1 diabetes mellitus patients.
Patients and Methods: Placebo-controlled, doubled blinded clinical trial method is utilized through which 60 type 1 DM patients allocated into two groups, 30 patients treated with insulin and silymarin 400 mg/day in two divided doses, while the other 30 patients treated with insulin and placebo for 60 days. Fasting serum gluco

pancreatic islets in which a process of programmed cell death (apoptosis) is elicited in the β-cells by interaction of activated T-cells and proinflammatory cytokines in the immune infiltrate. Interleukin-6 (IL-6) is a pleiotropic cytokine with a key impact on both immunoregulation and nonimmune events in many cell types .
Objective: to assess the level of serum IL-6 as an inflammatory marker in type 1 diabetic children, with correlation to FBG and HbA1c.
Subjects and methods: 45 type 1 diabetic child (20 males and 25 females), mean age 10.9± 3.4 years who attended the National Diabetic Center, Al-Mustansiria university were included in this study. 45 apparently healthy controls matched for age and sex were participated in this s